Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and Pharmacokinetics

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 1028-1036

  Kus, Kamil ^a,b   Walczak, Maria ^a,b   Maslak, Edyta ^a   Zakrzewska, Agnieszka ^a   Gonciarz Dytman, Anna ^a,b   Zabielski, Piotr ^c   Sitek, Barbara ^a   Wandzel, Krystyna ^a   Kij, Agnieszka ^a,b   Chabowski, Adrian ^c   Holland, Ryan J ^e   Saavedra, Joseph E ^d   Keefer, Larry K ^e   Chlopicki, Stefan ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; LIVER PROTECTIVE AGENT; O 2 VINYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O 2 VINYL [2 (CARBOXYLATO)PYRROLIDIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; UNCLASSIFIED DRUG; CYTOCHROME P450; FATTY ACID; NITRIC OXIDE DONOR; O(2)-VINYL-1-(PYRROLIDIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE; O2-VINYL 1-(2-(CARBOXYLATO)PYRROLIDIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE; PYRROLIDINE DERIVATIVE; TRIAZENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISTEATOTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVITY; EX VIVO STUDY; GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN RESISTANCE; LIPID COMPOSITION; LIVER PROTECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOTRANSFORMATION; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; GLUCOSE INTOLERANCE; INTESTINE ABSORPTION; KIDNEY; LIPID DIET; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; TISSUE DISTRIBUTION; WISTAR RAT;

MURINAE; MUS;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DIET, HIGH-FAT; FATTY ACIDS; GLUCOSE INTOLERANCE; INTESTINAL ABSORPTION; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE DONORS; NON-ALCOHOLIC FATTY LIVER DISEASE; PYRROLIDINES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TRIAZENES;

EID: 84940369765     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.063388     Document Type: Article

References (64)

1. An Z, Winnick JJ, Moore M.C., Farmer B., Smith M, Irimia JM, Roach P.J., and Cherrington AD (2012) A cyclic guanosine monophosphate-dependent pathway can regulate net hepatic glucose uptake in vivo. Diabetes 61:2433-2441.
2. Baranowski M, Blachnio-Zabielska AU, Zabielski P., Harasim E, Harasiuk D, Chabowski A., and Gorski J (2013) Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle. J Physiol Pharmacol 64:289-297.
3. Carnovale CE and Ronco MT (2012) Role of nitric oxide in liver regeneration. Ann Hepatol 11: 636-647.
4. Chakrapani H, Showalter BM, Kong L, Keefer L.K., and Saavedra JE (2007) V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO. Org Lett 9:3409-3412.
5. Cook S, Hugli O, Egli M., Vollenweider P, Burcelin R, Nicod P., Thorens B, and Scherrer U (2003) Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 133:360-363.
6. Deleve LD (2008) Sinusoidal obstruction syndrome. Gastroenterol Hepatol (N Y) 4:101-103.
7. DeLeve LD, Wang X, Kanel G.C., Ito Y., Bethea NW, McCuskey MK, Tokes ZA, Tsai J, and McCuskey RS (2003) Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 38:900-908.
8. de Oliveira CPMS, Simplicio FI, de Lima VMR, Yuahasi K, Lopasso FP, Alves VAF, Abdalla DSP, Carrilho FJ, Laurindo FRM, and de Oliveira MG (2006) Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats. World J Gastroenterol 12:1905-1911.
9. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
10. Duplain H, Burcelin R, Sartori C., Cook S, Egli M, Lepori M., Vollenweider P, Pedrazzini T, Nicod P., and Thorens B, et al. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104:342-345.
11. Edwards C, Feng H-Q, Reynolds C, Mao L., and Rockey DC (2008) Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol 294:G1311-G1317.
12. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki J.M., Linemeyer DL, and Bullough DA (2005) Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 312:554-560.
13. Förstermann U and Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33:829-837, 837a-837d.
14. Gong P, Cederbaum AI, and Nieto N (2004) The liver-selective nitric oxide donor O2-vinyl 1-(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate (V-PYRRO/NO) protects HepG2 cells against cy-tochrome P450 2E1-dependent toxicity. Mol Pharmacol 65:130-138.
15. González R., Cruz A, Ferrín G, López-Cillero P, Fernández-Rodríguez R, Briceño J, Gómez MA, Rufián S, Mata M de L, and Martínez-Ruiz A, et al. (2011) Nitric oxide mimics transcriptional and post-translational regulation during α-tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. J Hepatol 55:133-144.
16. Guengerich FP (1992) Characterization of human cytochrome P450 enzymes. FASEB J 6:745-748.
17. Han HK and Amidon GL (2000) Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2:E6.
18. Holownia A, Jablonski J, Skiepko A., Mroz R, Sitko E, and Braszko JJ (2009) Ruthenium red protects HepG2 cells overexpressing CYP2E1 against acetaminophen cytotoxicity. Naunyn Schmiedebergs Arch Pharmacol 379:27-35.
19. Hong SY, Borchert GL, Maciag A.E., Nandurdikar RS, Saavedra JE, Keefer LK, Phang J.M., and Chakrapani H (2010) The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline. ACS Med Chem Lett 1:386-389.
20. Hu LS, George J, and Wang JH (2013) Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol 19:1707-1717.
21. Huttunen KM, Mähönen N, Raunio H, and Rautio J (2008) Cytochrome P450-activated prodrugs: targeted drug delivery. Curr Med Chem 15:2346-2365.
22. Ijaz S, Yang W, Winslet M.C., and Seifalian AM (2005) The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis. Microvasc Res 70:129-136.
23. Inami K, Nims RW, Srinivasan A, Citro M.L., Saavedra JE, Cederbaum AI, and Keefer LK (2006) Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human mi-crosomal cytochromes P450. Nitric Oxide 14:309-315.
24. Jobgen W, Meininger CJ, Jobgen S.C., Li P., Lee M-J, Smith SB, Spencer T.E., Fried SK, and Wu G (2009) Dietary L-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J Nutr 139:230-237.
25. Jobgen WS, Fried SK, Fu W.J., Meininger CJ, and Wu G (2006) Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 17:571-588.
26. Kim YM, Chung HT, Simmons R.L., and Billiar TR (2000a) Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 275:10954-10961.
27. Kim YM, Kim TH, Chung H.T., Talanian RV, Yin XM, and Billiar TR (2000b) Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 32:770-778.
28. Le Gouill E., Jimenez M, Binnert C., Jayet PY, Thalmann S, Nicod P, Scherrer U., and Vollenweider P (2007) Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial beta-oxidation. Diabetes 56:2690-2696.
29. Li C, Liu J, Saavedra J.E., Keefer LK, and Waalkes MP (2003) The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced nephrotoxicity in mice. Toxicology 189:173-180.
30. Lin J, Schyschka L, Mühl-Benninghaus R, Neumann J, Hao L, Nussler N, Dooley S, Liu L, Stöckle U, and Nussler AK, et al. (2012) Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. Arch Toxicol 86:87-95.
31. Liu J, He Y-Y, Chignell CF, Clark J, Myers P., Saavedra JE, and Waalkes MP (2005) Limited protective role of V-PYRRO/NO against cholestasis produced by alpha-naphthylisothiocyanate in mice. Biochem Pharmacol 70:144-151.
32. Liu J, Li C, Waalkes M.P., Clark J., Myers P, Saavedra JE, and Keefer LK (2003) The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 37:324-333.
33. Liu J, Qu W, Saavedra J.E., and Waalkes MP (2004) The nitric oxide donor, O2-vinyl 1-(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate (V-PYRRO/NO), protects against cadmium-induced hepatotoxicity in mice. J Pharmacol Exp Ther 310:18-24.
34. Liu J, Saavedra JE, Lu T, Song J-G, Clark J, Waalkes M.P., and Keefer LK (2002) O(2)-Vinyl 1- (pyrrolidin-1-yl) diazen-1-ium-1,2-diolate protection against D-galactosamine/endotoxin-induced hepatotoxicity in mice: genomic analysis using microarrays. J Pharmacol Exp Ther 300:18-25.
35. Liu J and Waalkes MP (2005) Nitric oxide and chemically induced hepatotoxicity: beneficial effects of the liver-selective nitric oxide donor, V-PYRRO/NO. Toxicology 208:289-297.
36. Lowry OH, Rosebrough NJ, Farr A.L., and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
37. Lutz SZ, Hennige AM, Feil S, Peter A., Gerling A, Machann J, Kröber SM, Rath M., Schürmann A, and Weigert C, et al. (2011) Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes 60:1566-1576.
38. Maslak E, Zabielski P, Kochan K., Kus K, Jasztal A, Sitek B., Proniewski B, Wojcik T, Gula K., and Kij A, et al. (2015) The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochem Pharmacol 93:389-400.
39. Moal F, Chappard D, Wang J., Vuillemin E, Michalak-Provost S, Rousselet MC, Oberti F, Calès P (2002) Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 36(4 Pt 1), 840-9.
40. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
41. Ortiz de Montellano PR (2013) Cytochrome P450-activated prodrugs. Future Med Chem 5: 213-228.
42. Paine MF, Hart HL, Ludington S.S., Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
43. Pavek P and Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129-143.
44. Pawłowska M and Augustin E (2011) Expression systems of cytochrome P450 proteins in studies of drug metabolism in vitro. Postepy Hig Med Dosw 65:367-376.
45. Pfeifer A, Kilic A, and Hoffmann LS (2013) Regulation of metabolism by cGMP. Pharmacol Ther 140:81-91.
46. Qu W, Liu J, Dill A.L., Saavedra JE, Keefer LK, and Waalkes MP (2009) V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity. Cancer Sci 100: 382-388.
47. Qu W, Liu J, Fuquay R., Saavedra JE, Keefer LK, and Waalkes MP (2007) The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. Cancer Lett 256:238-245.
48. Qu W, Liu J, Fuquay R., Shimoda R, Sakurai T, Saavedra J.E., Keefer LK, and Waalkes MP (2005) The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level. Nitric Oxide 12:114-120.
49. Ricardo KFS, Shishido SM, de Oliveira MG, and Krieger MH (2002) Characterization of the hypotensive effect of S-nitroso-N-acetylcysteine in normotensive and hypertensive conscious rats. Nitric Oxide 7:57-66.
50. Ricciardi R, Foley DP, Quarfordt S.H., Saavedra JE, Keefer LK, Wheeler SM, Donohue S.E., Callery MP, and Meyers WC (2001) V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion. Transplantation 71:193-198.
51. Rockey DC and Shah V (2004) Nitric oxide biology and the liver: report of an AASLD research workshop. Hepatology 39:250-257.
52. Saavedra JE, Billiar TR, Williams D.L., Kim YM, Watkins SC, and Keefer LK (1997) Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver. J Med Chem 40:1947-1954.
53. Sadri P and Lautt WW (1999) Blockade of hepatic nitric oxide synthase causes insulin resistance. Am J Physiol 277:G101-G108.
54. Sansbury BE, Cummins TD, Tang Y, Hellmann J., Holden CR, Harbeson MA, Chen Y, Patel R.P., Spite M., and Bhatnagar A, et al. (2012) Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res 111:1176-1189.
55. Siriussawakul A, Zaky A, and Lang JD (2010) Role of nitric oxide in hepatic ischemia-reperfusion injury. World J Gastroenterol 16:6079-6086.
56. Stinson SF, House T, Bramhall C., Saavedra JE, Keefer LK, and Nims RW (2002) Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. Xenobiotica 32:339-347.
57. Tateya S, Rizzo NO, Handa P, Cheng A.M., Morgan-Stevenson V, Daum G, Clowes A.W., Morton GJ, Schwartz MW, and Kim F (2011) Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding. Diabetes 60:2792-2801.
58. Testa B (2009) Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Curr Opin Chem Biol 13:338-344.
59. van den Berg SA, Guigas B, Bijland S., Ouwens M, Voshol PJ, Frants R.R., Havekes LM, Romijn JA, and van Dijk KW (2010) High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. Nutr Metab (Lond) 7:24.
60. Warensjö E, Risérus U, and Vessby B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48:1999-2005.
61. Westerink WMA and Schoonen WGEJ (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581-1591.
62. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Harasim E., and Górski J (2009) Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 54:59-65.
63. Zabielski P, Baranowski M, Błachnio-Zabielska A, Zendzian-Piotrowska M, and Górski J (2010) The effect of high-fat diet on the sphingolipid pathway of signal transduction in regenerating rat liver. Prostaglandins Other Lipid Mediat 93:75-83.
64. Zawilska JB, Wojcieszak J, and Olejniczak AB (2013) Prodrugs: a challenge for the drug development. Pharmacol Rep 65:1-14.